Radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma: A retrospective, multi-center study

Lakhoo, Janesh; Adams, Ryan C.; Dave, Atman; Luo, Lin; Vargo, Christopher; Isaacson, Ari J.; Sher, Alex; Fischman, A.; Yee, D.; Ryan, Samantha; Patel, S.; Duchac, Debora; Brown, Daniel B.

doi:10.1016/j.ctarc.2020.100208

Cited by 5 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multi-center study from the United States revealed that the overall ORR and DCR of beads loaded with doxorubicin were 47.6% and 76.8%, respectively, for advanced HCC. 20 Another single-center study in Greece showed ORR and SD was seen in 68.9% and 20% of 45 HCC patients using HepaSphere DEB-TACE. 23 Urbano et al conducted a prospective multicenter study in Spain, including 131 patients with liver cancer receiving 214 times of D-TACE treatment.…”

Section: Discussionmentioning

confidence: 97%

“…However, drug-loaded microspheres are combined with chemotherapeutic drugs through ion exchange, and the chemotherapeutic drugs can be released slowly after the microspheres are injected into the tumor through a catheter, which has better pharmacokinetic advantages. 20 Although the clinical efficacy of DEB-TACE and c-TACE remains controversial, growing evidence has shown that the former obtained better survival benefits for advanced liver cancer. Results from a metaanalysis including 3438 patients with liver cancer treated with TACE showed that DEB-TACE had better 1-year, 2-year, and 3-year survival rates than cTACE, with relative risk ratios of 0.79, 0.89, and 0.89, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer

Zhang

Guo²,

et al. 2021

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Purpose The optimal microparticle size for drug‐eluting beads transarterial chemoembolization (DEB‐TACE) remains unknown. This retrospective cohort study analyzed the efficacy and safety of CalliSpheres microsphere embolization in the treatment of unresectable hepatocellular carcinoma (HCC) to determine the influence of particle size on the results. Patients and methods Forty‐two patients with unresectable HCC were enrolled in this retrospective study from January 2018 to January 2020. Patients received DEB‐TACE with CalliSpheres of 100–300 μm (small‐size, n = 15) or 300–500 μm (medium‐size, n = 27). The tumor response was evaluated via enhanced CT or MRI at 1 month, 3 months, and 6 months after treatment, based on the Modified Response Evaluation Criteria in Solid Tumors. Adverse events after DEB‐TACE were recorded. Results Complete response, partial response, stable disease, and progressive disease were recorded in 20%, 20%, 33.3%, 26.7%, respectively, of patients in the small‐size group and 3.7%, 25.9%, 44.4%, 25.9% of patients in the medium‐size group, respectively. No significant difference was found between the two groups (p = 0.516). Major adverse events, including grade three liver toxicity (n = 4) and liver abscess (n = 3), occurred significantly more in the small‐size group, while none were reported in the medium size group (p < 0.05). Conclusion DEB‐TACE with medium‐size (300–500 μm) CalliSpheres microspheres had similar efficacy and a better safety profile than DEB‐TACE with small‐size (100–300 μm) CalliSpheres, indicating that medium‐size microspheres may be a better choice for unresectable primary liver cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer

Zhang

Guo²,

et al. 2021

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…In the USA, LC Beads LUMI TM are commercialized in two ranges: 70-150 and 40-90 µm. In a retrospective multi-center study that included 82 patients Lakhoo et al showed an OR and disease control rate (DCR) of 47.6% (CR 19.5%) and 76.8%, respectively [35]. Grade 3 adverse events were seen in 6.1% of patients.…”

Section: Heading Toward a Standardization Of Tace-development Of Drug Eluting Microspheres (Dems)mentioning

confidence: 99%

In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?

Bucalau

Tancredi

Verset

2021

Cancers

View full text Add to dashboard Cite

Conventional transarterial embolization (cTACE) has been proven to be effective for intermediate stage hepatocellular carcinoma (HCC), with a recent systematic review showing an overall survival (OS) of 19.4 months. Nevertheless, due to the rapid development of the systemic therapeutic landscape, the place of TACE is becoming questionable. Is there still a niche for TACE in the era of immunotherapy and combination treatments such as atezolizumab–bevacizumab, which has shown an OS of 19.2 months with excellent tolerance? The development of drug-eluting microspheres (DEMs) has led to the standardization of the technique, and along with adequate selection, it showed an OS of 48 months in a retrospective study. In order to increase treatment selectivity, new catheters have also been added to the TACE arsenal as well as the use of cone-beam CT (CBCT), which provides three-dimensional volumetric images and guidance during procedures. Moreover, the TACE indications have also widened. It may serve as a “bridging therapy” for liver transplantation candidates while they are on the waiting list, and it represents a valuable downstaging tool to transplantation criteria. The aim of this review is to explore the current data on the advancements of TACE and its future place amongst the growing panel of treatments.

show abstract

“…Other ways to guide percutaneous ablation devices is through the use of lipiodol or radiopaque beads. These are sometimes used in transarterial chemoembolization and can enhance intraprocedural imaging guidance by their ability to be visualized with fluoroscopy or CT [ 20 , 21 ]. Other ways to guide percutaneous ablation devices is via pre-ablation embolization of lesions using lipiodol or radiopaque beads.…”

Section: Imaging Modalities For Guiding Percutaneous Ablation Devicesmentioning

confidence: 99%

“…Other ways to guide percutaneous ablation devices is via pre-ablation embolization of lesions using lipiodol or radiopaque beads. These are used in transarterial chemoembolization and can enhance intraprocedural imaging guidance by their ability to be visualized by fluoroscopy or CT [ 20 , 21 ].…”

Section: Imaging Modalities For Guiding Percutaneous Ablation Devicesmentioning

confidence: 99%

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

et al. 2022

View full text Add to dashboard Cite

Image-guided percutaneous ablation methods have been further developed during the recent two decades and have transformed the minimally invasive and precision features of treatment options targeting primary and metastatic tumors. They work by percutaneously introducing applicators to precisely destroy a tumor and offer much lower risks than conventional methods. There are usually shorter recovery periods, less bleeding, and more preservation of organ parenchyma, expanding the treatment options of patients with cancer who may not be eligible for resection. Image-guided ablation techniques are currently utilized for the treatment of primary and metastatic tumors in various organs including the liver, pancreas, kidneys, thyroid and parathyroid, prostate, lung, bone, and soft tissue. This article provides a brief review of the various imaging modalities and available ablation techniques and discusses their applications and associated complications in various organs.

show abstract

Radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma: A retrospective, multi-center study

Cited by 5 publications

References 27 publications

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer

In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

Contact Info

Product

Resources

About